Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 4, July-August, p. 725–732

doi: 10.17219/acem/59959

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Second-Line Chemotherapy of Advanced Colorectal Cancer: Predictive and Prognostic Factors

Krzysztof Forgacz1,A,B,C,D, Anil K. Agrawal2,A,E,F, Tomasz Sawicki2,B, Grzegorz W. Marek2,D,E

1 Clinical Oncology Ward, Miedziowe Centrum Zdrowia S.A., Lubin, Poland

2 2nd Clinic of General and Oncological Surgery, Wroclaw Medical University, Poland

Abstract

Background. Colorectal cancer progression presents a significant clinical problem. After its dissemination, the foundation of its treatment comprises of palliative chemotherapy.
Objectives. The aim of this study was to assess the predictive and prognostic value of clinical response to second line treatment (with capecitabine or with a two-drug regimen including irinotecan) and to analyze its relation to selected clinical and pathological variables with respect to time to disease progression.
Material and Methods. The retrospective analysis of 164 patients with advanced colorectal cancer treated in 2001– –2008 included chosen clinical, pathological and follow-up data.
Results. Response to second-line chemotherapy was observed in 34 out of 164 patients: In 18/82 in the irinotecan group (22%) and in 16/82 in the capecitabine group (19.5%). The mean survival time to progression following the second line of treatment amounted to 5.85 and 6.2 months respectively. Statistically, a higher number of patients in good condition of 0 to 1 was documented in the group responding to treatment. Significant correlation was documented between primary stage of the disease and time to progression in patients treated with capecitabine (p = 0.0258). The recurrence of the disease was observed in 44/45 patients following operation with radical intention but with an insufficient number of excised lymph nodes. A significantly longer time to progression was observed in women treated with capecitabine. In logistic regression, lack of treatment response was found to be an independent factor affecting the time to disease progression. Patients who did not respond to the second line of treatment demonstrated a significantly shorter time to disease progression than patients who responded to it and they showed a significantly higher number of patients with leucopenia during treatment.
Conclusion. Clinical response to treatment in both treated groups is of significant importance for the probability of local recurrence of the disease, preservation of a good patient’s condition and the higher level of leukocytes during treatment.

Key words

colorectal cancer, adjuvant chemotherapy, predictive factors, therapeutic response, time to progression

References (30)

  1. Utracka-Hutka B, Nowara E, Słomian G, Suwiński R: Evaluation of tolerance and efficacy of palliative chemotherapy with irinotecan in patients with colorectal carcinoma [in Polish]. Współcz Onkol 2003, 17, 767–771.
  2. Venook A: Critical evaluation of current treatments in metastatic colorectal cancer. The Oncologist 2005, 10, 250–261.
  3. Krzakowski M, Bujko K, Jassem J, Krzemieniecki K, Wojtkiewicz M: Systemic treatment of colorectal carcinoma: Recommendations based on results of clinical studies [in Polish]. Onkol Prakt Klin 2007, 3, 267–285.
  4. Van Cutsem E, Oliveira J: On behalf of the ESMO Guidelines Working Group. Colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2008, 19, 29–30.
  5. Kocik J, Ziarkiewicz M, Świeboda-Sadlej A, Staszewska-Skurczyńska M, Jeleniak H, Żórawińska E, Vyas P: Potential for combined treatment of patients with disseminated colorectal carcinoma [in Polish]. Onkol Prakt Klin 2008, 6, 213–218.
  6. Van Cutsem E, Nordlinger B, Adam R: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006, 42, 2212–2221.
  7. Joseph N, Sigurdson E, Hanlon A: Accuracy of Determining Nodal Negativity in Colorectal Cancer on the Basis of the Number of Nodes Retrieved on Resection. Ann Surg Oncol 2003, 10, 213–218.
  8. Grzebieniak Z, Szynglarewicz B: Prognostic factors in colorectal cancer [in Polish]. Przegl Lek 2004, 61, 43–50.
  9. Herald RJ, Husband EM, Ryall RDH: The mesorectum in rectal cancer surgery – the clue to pelvic recurrence? Br J Surg 1994, 81, 1227–1229.
  10. Peeters KC, Marijnen CA, Nagtegaal ID: The TME trial after a median follow-up of 6 years: Increased local control, but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007, 246, 693–701.
  11. Nowacki M: Progress in treatment of large intestine tumours in the year of 2003 [in Polish]. Med Prakt – Chirurgia 2004, 148, 152.
  12. Szynglarewicz B, Matkowski R, Smorąg Z: Cancer of the rectum in male patients: Factor influencing overall survival following anterior resection with mesorectal excision for rectal cancer. Przegl Gastrol 2007, 2, 125–129.
  13. Gill S, Loprinzi CL, Sargent DJ: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004, 15, 22, 1797–1806.
  14. Hodgson DC, Hang W, Zaslavsky AM: Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst 2003, 95, 708–716.
  15. McArdle CS, Hole D: Outcome following surgery for colorectal cancer. Br Med Bull 2002, 64, 119–125.
  16. Obrand DI, Gordon PH: Incidence and pattern of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997, 40, 15–24.
  17. Nowacki MP, Nowakowska D, Rutkowski A: Colorectal cancer [in Polish]. Nowotwory 1998, 48, 195–214.
  18. Nordlinger B, Van Cutsem E, Gruenberger T: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: Recommendations from an expert panel. Ann Oncol 2009, 20, 985–992.
  19. Stańczyk M, Olszewski W, Gewartowska M, Maruszyński M: Role of lymphatic system in development of metastases of colorectal carcinoma. Lymphangiogenesis or lymphoedema in neopolastic tissue? [in Polish]. Pol Merk Lek 2007, XXII, 131, 457–459.
  20. Świętoniowski G, Brużewicz Sz, Kuniej T, Suder E, Kłaniewski T, Molenda W: Effect of the number of examined lymph nodes on quality of N+ trait evaluation in patients radically treated due to colorectal carcinoma [in Polish]. Współcz Onkol 2008, 12, 8, 380–383.
  21. Grzela M, Windorbska W, Makarewicz R: Evaluation of regional lymph nodes in the course of combined rectal cancer [in Polish]. Współcz Onkol 2005, 9, 246–249.
  22. O’Brien MJ, Winawer SJ, Zauber AG: The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990, 98, 371–379.
  23. Andre T, Boni C, Mounedji-Boudiaf L: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N England J Med 2004, 350, 2343–2351.
  24. Van Cutsem E, Dicato M, Haustermans K: The diagnosis and management of rectal cancer: Expert discussion and recommendations derived from 9th World Congress on Gastrointestinal Cancer. Ann Oncol 2008, 19, Suppl 6, 1–8.
  25. Popiela T, Kulik J, Richter P, Milanowski W: Distant results of combined treatment in colorectal carcinoma [in Polish]. J Oncol 2006, 56, 38–44.
  26. Finn OJ: Cancer Immunology. N Engl J Med 2008, 358, 2704–2715.
  27. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P: Lymphocytes CD3+ in invasive margin of deeply infiltrating (pT3-T4) colorectal cancer and risk of metastases development following operation: Invasive examination. Lancet Oncol 2009, 10, 9, 877–884.
  28. Pasz-Walczak G, Jesionek-Kupnicka G, Kubiak R, Kordek R: Principal mechanisms of carcinogenesis in large intestine [in Polish]. Współ Onkol 2004, 8, 303–307.
  29. Łaczmańska I, Kozowska J: Chromosomal instability in sporadic colorectal carcinoma [in Polish]. Współ Onkol 2009, 13, 177–180.
  30. Turoldo A, Balani A, Scaramucci M: Preoperative CEA: Prognostic significance in colorectal carcinoma. Tumori 2003, 89, 95–97.
© Wroclaw Medical University